<DOC>
	<DOCNO>NCT01206504</DOCNO>
	<brief_summary>This study test experimental drug call MGAWN1 treatment West Nile infection .</brief_summary>
	<brief_title>Expanded Access MGAWN1 Subjects With Suspected West Nile Neuroinvasive Disease ; Suspected West Nile Virus Infection ; Substantial Accidental Exposure</brief_title>
	<detailed_description>The objective study provide expand access MGAWN1 ; study intend subject eligible access non-expanded access protocol .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>West Nile Fever</mesh_term>
	<criteria>1 . For West Nile Neuroinvasive Disease subject : Have neurological sign and/or symptom West Nile meningitis , encephalitis , and/or acute flaccid paralysis 2 . For immunocompromised subject suspect West Nile virus infection : Receiving immunosuppressive treatment disease , autoimmune disease , transplant recipient ; Have receive organ tissue cell donor likely infect West Nile virus ( show serology PCR/NAT donor , organ , tissue ) Have acquire immunodeficiency ( immunosuppressive treatment receive infected transplant ) congenital immunodeficiency 3 . For subject substantial exposure West Nile virus : Exposure route , include percutaneous , inhalation , mucosal exposure ( might occur laboratory accident ) 4 . Develop sign and/or symptom within 14 day study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>West Nile virus</keyword>
	<keyword>WNV</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Acute Flaccid Paralysis</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>WNND</keyword>
	<keyword>West Nile Neuroinvasive Disease</keyword>
	<keyword>Accidental Exposure West Nile Virus</keyword>
</DOC>